Rga1 Inhibitors
Chemical inhibitors of Rga1 can exert their effects through various mechanisms by targeting different enzymes and kinases that are part of signaling pathways which regulate the activity of Rga1. LY294002 and Wortmannin, for instance, are inhibitors of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, these chemicals can prevent the activation of downstream signaling pathways that are necessary for the proper functioning of Rga1. Rapamycin acts on a different molecular target, inhibiting mTOR, which leads to a reduction in the activation of pathways that may include those regulating Rga1's activity. Similarly, PP2, as a Src family kinase inhibitor, can affect multiple signaling pathways that converge on the regulation of Rga1, leading to its indirect inhibition.
Other chemical inhibitors such as PD98059, U0126, and SL327 specifically target MEK1/2, which are upstream kinases in the MAPK/ERK pathway. Inhibition of these kinases leads to a decrease in the MAPK/ERK signaling, which can result in reduced Rga1 activity. SB203580 and SP600125 target other components of the MAPK pathway, with SB203580 inhibiting p38 MAP kinase and SP600125 inhibiting JNK. These inhibitors, therefore, can indirectly decrease Rga1 activity by modulating the MAPK pathway. Additionally, Y-27632 inhibits the Rho/ROCK pathway, which could affect Rga1 activity due to the interconnectedness of intracellular signaling routes. Lastly, BIBU 1361 and Sunitinib, as tyrosine kinase inhibitors, can lead to decreased Rga1 activity by affecting the tyrosine kinase signaling pathways, which play a role in the regulation of Rga1. Each of these chemical inhibitors targets a specific molecule within the signaling pathways, but all converge on the modulation of Rga1 activity through their respective inhibitory actions.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a broad-spectrum inhibitor of phosphoinositide 3-kinases (PI3K), which indirectly inhibits Rga1 by preventing the activation of downstream signaling pathways that are necessary for Rga1's GTPase activating function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 specifically inhibits MEK1, which is upstream of the MAPK/ERK pathway. This inhibition reduces the activation of this pathway, which can lead to reduced Rga1 activity, as Rga1's function is related to MAPK signaling modulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 serves as an inhibitor of p38 MAP kinase, impacting the MAPK pathway. Inhibition of p38 MAPK can decrease Rga1 activity because Rga1 operates within the realm of MAPK pathway regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. By inhibiting JNK, SP600125 can decrease Rga1 activity, as Rga1 is associated with MAPK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is known to inhibit MEK1/2, which are critical kinases in the MAPK/ERK pathway. By inhibiting MEK1/2, U0126 can lead to decreased Rga1 activity, as Rga1's function is influenced by this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that by inhibiting PI3K, can reduce the downstream activation of kinases and signaling pathways that are necessary for Rga1's function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and by inhibiting mTOR, it can reduce the activation of downstream pathways that may include pathways regulating Rga1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a Src family kinase inhibitor. Src kinase activity is involved in multiple signaling pathways that could intersect with Rga1's regulatory functions; thus, PP2 can indirectly inhibit Rga1 activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which through inhibition of the Rho/ROCK pathway, may impede downstream effects that influence Rga1 activity within the cell. | ||||||
PQ401 | 196868-63-0 | sc-221738 | 10 mg | $146.00 | ||
BIBU 1361 is a tyrosine kinase inhibitor that by affecting the tyrosine kinase signaling can indirectly inhibit Rga1 activity as Rga1 is modulated by various signaling pathways involving tyrosine kinases. | ||||||